Capricor Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Capricor Therapeutics
CAPR Stock  USD 8.18  1.44  21.36%   
Capricor Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Capricor Therapeutics' valuation are provided below:
Gross Profit
-40.4 M
Market Capitalization
308.1 M
Enterprise Value Revenue
9.6079
Revenue
17.4 M
Earnings Share
(1.37)
There are over one hundred nineteen available fundamental signals for Capricor Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Capricor Therapeutics' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 07/30/2025, Market Cap is likely to grow to about 510.3 M. Also, Enterprise Value is likely to grow to about 500 M

Capricor Therapeutics Total Revenue

23.38 Million

Check Capricor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Capricor Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2 M or Other Operating Expenses of 68.1 M, as well as many indicators such as Price To Sales Ratio of 20.73, Dividend Yield of 0.0 or PTB Ratio of 3.51. Capricor financial statements analysis is a perfect complement when working with Capricor Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Capricor Stock
Check out the analysis of Capricor Therapeutics Correlation against competitors.
To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Capricor Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets179 M170.5 M39.5 M
Slightly volatile
Total Current Liabilities22.1 M21 M8.1 M
Slightly volatile
Accounts Payable7.5 M7.2 M2.8 M
Slightly volatile
Non Current Assets Total7.5 M7.1 M2.8 M
Slightly volatile
Non Currrent Assets Other232.8 K221.7 K125.3 K
Slightly volatile
Common Stock Total Equity20.1 K29 K21.9 K
Very volatile
Common Stock Shares Outstanding37 M35.2 M11.7 M
Slightly volatile
Liabilities And Stockholders Equity179 M170.5 M39.5 M
Slightly volatile
Other Stockholder Equity361.4 M344.2 M105 M
Slightly volatile
Total Liabilities26.3 M25 M13.9 M
Slightly volatile
Common Stock47.9 K45.6 K21.3 K
Slightly volatile
Cash8.2 M11.3 M10.4 M
Slightly volatile
Cash And Short Term Investments159.1 M151.5 M33.5 M
Slightly volatile
Net Receivables10.9 M10.4 M2.2 M
Slightly volatile
Total Current Assets171.6 M163.4 M36.7 M
Slightly volatile
Other Current Liabilities8.6 M8.2 M1.6 M
Slightly volatile
Short and Long Term Debt Total1.4 M1.5 M5.5 M
Pretty Stable
Short Term Debt793.1 K834.8 K3.5 M
Slightly volatile
Property Plant And Equipment Net7.2 M6.9 M2.3 M
Slightly volatile
Other Current Assets775.1 K1.5 M777.3 K
Slightly volatile
Property Plant And Equipment Gross10.8 M10.3 M3 M
Slightly volatile
Capital Surpluse179.6 M171 M85.8 M
Slightly volatile
Property Plant Equipment5.5 M5.3 M1.7 M
Slightly volatile
Non Current Liabilities Total5.5 M4 M5.9 M
Pretty Stable
Non Current Liabilities Other3.6 M3.9 M2.6 M
Slightly volatile
Other Liabilities15.5 M14.8 M5.2 M
Slightly volatile
Long Term Debt Total4.9 M3 M6.5 M
Slightly volatile
Short and Long Term Debt210.9 K222 K4.4 M
Slightly volatile
Net Invested Capital152.7 M145.5 M30.9 M
Slightly volatile
Net Working Capital149.5 M142.4 M32.7 M
Slightly volatile
Capital Stock28.8 K45.6 K29 K
Very volatile

Capricor Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.5 M1.4 M356.6 K
Slightly volatile
Other Operating Expenses68.1 M64.8 M22 M
Slightly volatile
Total Operating Expenses66.6 M63.4 M20.4 M
Slightly volatile
Selling And Marketing Expenses15.5 B14.7 B8.3 B
Slightly volatile
Selling General Administrative14.9 M14.2 M6 M
Slightly volatile
Total Revenue23.4 M22.3 M5.7 M
Slightly volatile
Research Development52.5 M50 M16.3 M
Slightly volatile
Interest Income81 K85.3 K183.7 K
Slightly volatile
Reconciled Depreciation1.5 M1.4 M392.5 K
Slightly volatile

Capricor Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.5 M1.4 M356.7 K
Slightly volatile
Total Cash From Financing Activities160.4 M152.8 M29.5 M
Slightly volatile
Begin Period Cash Flow15.4 M14.7 M9.2 M
Slightly volatile
Other Cashflows From Financing Activities738.3 K450.2 K1 M
Pretty Stable
Stock Based Compensation10.3 M9.8 M3.1 M
Slightly volatile
Net Borrowings272 K286.3 K2.1 M
Slightly volatile
Issuance Of Capital Stock159.9 M152.3 M27.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio20.7321.823454.2011
Very volatile
Days Sales Outstanding266170406
Slightly volatile
Average Payables5.2 M5 M2.3 M
Slightly volatile
Stock Based Compensation To Revenue0.420.43853.6223
Slightly volatile
Capex To Depreciation1.031.07983.0983
Pretty Stable
EV To Sales20.3121.381739.2135
Pretty Stable
Sales General And Administrative To Revenue0.610.63835.1399
Pretty Stable
Research And Ddevelopement To Revenue2.132.24379.3543
Pretty Stable
Capex To Revenue0.06560.06910.8395
Very volatile
Cash Per Share4.094.30225.0228
Slightly volatile
Intangibles To Total Assets1.0E-41.0E-40.0406
Slightly volatile
Current Ratio3.977.77066.2935
Pretty Stable
Receivables Turnover2.042.14795.9888
Pretty Stable
Capex Per Share0.04150.04370.5982
Slightly volatile
Average Receivables5.2 M4.9 M2.4 M
Slightly volatile
Revenue Per Share0.60.63232.3985
Slightly volatile
Interest Debt Per Share0.03910.04122.4235
Slightly volatile
Debt To Assets0.00810.008519.4188
Slightly volatile
Graham Number8.559.6210.4853
Slightly volatile
Operating Cycle266170406
Slightly volatile
Effective Tax Rate0.00.00.0
Slightly volatile
Long Term Debt To Capitalization0.00280.00290.6455
Slightly volatile
Quick Ratio3.977.77066.2935
Pretty Stable
Net Income Per E B T8.0E-49.0E-40.001
Slightly volatile
Cash Ratio0.510.53683.3298
Pretty Stable
Cash Conversion Cycle266170406
Slightly volatile
Days Of Sales Outstanding266170406
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.071.03850.9763
Very volatile
Fixed Asset Turnover3.083.239813.3291
Slightly volatile
Debt Ratio0.00810.008519.4188
Slightly volatile
Price Sales Ratio20.7321.823454.2011
Very volatile
Asset Turnover0.120.130628.8978
Slightly volatile
Gross Profit Margin0.921.031.1271
Slightly volatile

Capricor Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap510.3 M486 M105 M
Slightly volatile
Enterprise Value500 M476.2 M99.3 M
Slightly volatile

Capricor Fundamental Market Drivers

Cash And Short Term Investments151.5 M

Capricor Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Capricor Therapeutics Financial Statements

Capricor Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Capricor Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Capricor Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12 M8 M
Total Revenue22.3 M23.4 M
Cost Of Revenue1.4 M1.4 M
Stock Based Compensation To Revenue 0.44  0.42 
Sales General And Administrative To Revenue 0.64  0.61 
Research And Ddevelopement To Revenue 2.24  2.13 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.63  0.60 
Ebit Per Revenue(1.91)(2.01)

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Capricor Stock

  0.6MGRM Monogram OrthopaedicsPairCorr
  0.47BTC BTC HealthPairCorr
  0.47ZOTA Zota Health CarePairCorr
  0.44METROPOLIS Metropolis HealthcarePairCorr
  0.4JNJ Johnson JohnsonPairCorr
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY